Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma

NCT00082888 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00082888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00082888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2004
Completion date
July 5, 2017
Enrollment
93 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, mature t-cell and nk-cell non-hodgkin lymphoma, nodal marginal zone lymphoma, recurrent adult hodgkin lymphoma, recurrent adult t-cell leukemia/lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, splenic marginal zone lymphoma